AXSM—The +5% response to the phase-3 migraine data is surprisingly tepid. Some investors may not have realized how hard it was to hit all the primary and secondary endpoints, thereby baking in an unduly high probability of success.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.